INTRODUCTION
 There is a paucity of evidence about the most well-defined, reliable, reproducible, and feasible methods for measuring efficacy outcomes in Acute bacterial skin and skin structure infections (ABSSSI) trials for targeted patient populations. Establishing an endpoint for clinical trials of ABSSSI, especially those conducted for registrational purposes, is essential.
 For ABSSSI, evidence suggests a relationship between a decrease in lesion size and patient-centered outcomes related to pain; however, there are no patient-reported outcome (PRO) measures to capture additional symptoms which patients may experience. Consequently, The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and ICON plc is developing a validated, reliable patientreported outcome (PRO) measure to assess symptoms of ABSSSI, including wound infection, cellulitis, erysipelas, or abscess, and their impact on how patients with an ABSSSI feel and functions.
PURPOSE
 The purpose of this study was to develop a patient-reported outcome (PRO) instrument to assess ABSSSI symptoms in patients in clinical trials of antibacterial drugs, consistent with FDA PRO Guidance.
METHODS
 A comprehensive review of the literature and interviews with nine US and European clinical experts informed the development of a concept elicitation (CE) interview guide, and a hypothetical conceptual framework and disease model exploring patients' experience with symptoms of ABSSSI. CE was based on telephone interviews with 34 patients, after which saturation of emergent concepts was reached. Items and response options were generated based on the qualitative data and a draft instrument was prepared with input and review from an international project team of academic and industry antibacterial experts.
 Subsequently, cognitive debriefing interviews were conducted with 15 ABSSSI patients, who had not participated in the original elicitation interviews, and 3 clinical experts to assess item readability, relevance, comprehensiveness, and content validity.
RESULTS -CONCEPT ELICITATION
 CE subtypes were evaluated and included 13 (38.2%) patients with major abscess, 12 (35.3%) with wound infection, and 9 (26.5%) with cellulitis. In terms of severity, the majority (79.4%) of infections were rated as moderate by clinicians. The mean age of patients was 38.8 years; 64.7% male. Symptoms were common across all ABSSSI subtypes and supported the saturation of concepts. The frequency of themes and concepts from the concept elicitations are presented by ABSSSI subgroup (Table 1) .
CONCLUSIONS
 SKINFECT is a PRO instrument developed to evaluate ABSSSI patient symptoms and functioning in clinical studies with documented evidence of content validity.
 Qualitative data from patients and input from experts formed the basis of the SKINFECT PRO structure and item pool, and it is now ready for psychometric reliability and validity testing. Table 2 .
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